In patients with SCC, mutations in the tumor suppressor gene TP53 are considered the most frequent, but genetic alterations in other cancer-related genes, such as cyclin-dependent kinase inhibitor 2A (CDKN2A), NOTCH1/2 and RAS, as well as chromosomal rearrangements have been found [7]. Here, CDKN2A is linked to cancer.